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TranscriptionHuman herpesvirus 8 (HHV-8) is associated with Kaposi's sarcoma (KS), an endothelial cell lesion believed
to be initiated and driven primarily by cytokine dysregulation. Among the viral proteins suspected as
contributing to viral pathogenesis is the lytically expressed viral G protein-coupled receptor (vGPCR), which
can induce various cellular cytokines. CC ligand-2 (CCL2/MCP-1) is a vGPCR-regulated angiogenic
chemokine found at elevated levels in KS lesions and induced by HHV-8 infection of endothelial cells.
Here we show that vGPCR induces CCL2 in endothelial cells via activation of C/EBPβ and that vGPCR and C/
EBPβ are critical components of CCL2 induction by HHV-8 infection of endothelial cultures. To our
knowledge, this is the ﬁrst report of vGPCR-mediated cytokine induction, and its characterization, in the
context of virus infection. Our results identify a mechanism by which vGPCR can contribute, in a host cell
shutoff-independent manner, to viral pathogenesis.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human herpesvirus 8 (HHV-8) has been linked to Kaposi's
sarcoma (KS) in addition to certain B-cell lymphomas (Ablashi et al.,
2002; Chang et al., 1994; Hengge et al., 2002). There is substantial
evidence that the development of KS is in large part driven by
angiogenic and pro-inﬂammatory cytokine dysregulation, and the
contribution of HHV-8 to the onset and progression of disease is
generally thought to involve induction of such cytokines to promote
endothelial cell proliferation and angiogenesis characteristic of KS
(Ensoli et al., 2001; Jensen and Lira, 2004). Several HHV-8 encoded
proteins have been implicated in this process. The signal transducing
membrane proteins speciﬁed by ORFs K1 and K15 have been reported
to induce KS-associated cytokines such as VEGF, IL-6 and CXCL8
(Brinkmann et al., 2007; Lee et al., 2005; Prakash et al., 2005;
Samaniego et al., 2001; Wang et al., 2004), viral interleukin-6 can
induce expression of VEGF and CCL2, for example (Aoki et al., 1999;
Fielding et al., 2005), and multiple angiogenic cytokines, including
VEGF, CCL2, CXCL1, CXCL8, IL-1β, bFGF, and angiopoietin-2, are
induced by the viral G protein-coupled receptor (vGPCR) speciﬁed by
ORF74 (Bais et al., 1998; Martin et al., 2008; Pati et al., 2001; Schwarz
and Murphy, 2001; Vart et al., 2007). Such cytokines could contribute
to the onset and progression of KS.When introduced intomice, vGPCRll rights reserved.is able to induce lesions that resemble KS (Montaner et al., 2003; Yang
et al., 2000). Importantly, this is possible with expression of vGPCR in
only a small minority of cells in the tumor, implicating receptor-
induced cytokines (i.e., paracrine signaling) in this process. Indeed, all
available evidence indicates that vGPCR is expressed exclusively
during lytic replication rather than latency (Chiou et al., 2002; Jeong
et al., 2001; Kirshner et al., 1999; Nador et al., 2001), suggesting that
only paracrine contributions of vGPCR to KS are possible. However,
only those cytokines that can escape virus-induced host cell shutoff
(destabilization of cellular mRNAs) are potentially available to
contribute to viral pathogenesis in this way (Glaunsinger and
Ganem, 2004a, 2004b). CCL2, the focus of this manuscript, is a
cytokine that can both escape host-cell shutoff and potentially
contribute via its pro-angiogenic activity to KS.
While many studies of vGPCR activity in respect of signal
transduction, induced cellular genes, and effects on cell growth in
vitro and in vivo have been reported using vGPCR-transduced cells,
investigations of vGPCR activity in the context of HHV-8 infection are
lacking. In view of this and the potential of vGPCR to contribute to KS
pathogenesis via cytokine induction, within the restrictions imposed
by widespread host cell shutoff, we wanted to investigate the
mechanisms of vGPCR-mediated angio-cytokine induction in the
context of virus infection as well as in isolation. Our data identify CCL2
as a cytokine induced robustly by vGPCR in endothelial cells,
determine thatMAPK-activated C/EBPβ is necessary for the induction,
and demonstrate the relevance of vGPCR and C/EBPβ for CCL2
induction during HHV-8 infection of endothelial cells.
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To provide a means of analyzing vGPCR function in endothelial
cells, we used commercially available retroviral vectors (Tet-On
Advanced, Clontech) to generate telomerase immortalized endothelial
(TIME) cells (Venetsanakos et al., 2002) in which vGPCR expression
was inducible by doxycycline (Dox) treatment. These TIME-vGPCR
cells showed appropriate Dox-inducible expression of vGPCR, as
determined by immunoﬂuorescence assay and western blotting (Fig.
1A), in addition to qRT-PCR analysis (N500-fold induction, data not
shown). A focused gene array representing angiogenic cytokines and
regulators (see Materials and Methods) was used to identify vGPCR-
regulated genes via hybridization of cRNA probes derived from Dox-
treated versus untreated TIME-vGPCR cells. While vGPCR affected
expression of several genes (data not shown), CCL2 showed
particularly strong induction (Fig. 1B). The array data were conﬁrmed
by qRT-PCR analysis of RNA extracted from TIME-vGPCR cells
maintained in the absence and presence of Dox; there was a marked
induction (N6-fold) of CCL2 mRNA expression in response to Dox
(Fig. 1C, left). Similarly, Dox treatment was able to induce expression
of secreted CCL2, detected and quantiﬁed using ELISA assay (Fig. 1C,
right). CCL2 was produced in biologically signiﬁcant amounts, the
concentration in culture media achieved during the 24-h induction
period reaching 9 ng/ml (approximating the ED50 for chemoattrac-
tion). Our data were consistent with previous reports of robust
induction of CCL2 mRNA and protein by vGPCR (Martin et al., 2008;
Schwarz and Murphy, 2001). As CCL2 has been demonstrated to be
expressed in KS lesions, to be induced by HHV-8 infection of
endothelial cells (and therefore not subject to host cell shutoff), and
to signal in endothelial cells to promote angiogenesis (Caselli et al.,Fig. 1. Induction of CCL2 in vGPCR-transduced endothelial cells. (A) Testing of Tet-responsiv
inducible expression of vGPCR, visualized by using vGPCR rabbit antiserum (Chiou et al., 2002
vector. (B) Membrane hybridization analysis of CCL2 mRNA expression in TIME-vGPCR ce
maintained in medium containing serum or serum-starved (to remove possible effects of ser
cultures were used to generate biotin-labeled cRNA probes for array hybridization (Mate
normalization control (RPSS27a, ribosomal protein) are shown. (C) Veriﬁcation of array dat
and ELISA quantitation of secreted protein (right) in Dox treated and untreated TIME-vGPCR
time PCR reactions; bars indicate deviations from the mean values of paired PCR reactions. Fo
calculated from parallel standard curve values.2007; Salcedo et al., 2000; Sciacca et al., 1994; Stamatovic et al., 2006;
Uccini et al., 2003), we sought characterize the mechanism of vGPCR-
mediated CCL2 induction.
RNA polymerase II (PolII)-based chromatin immunoprecipitation
(ChIP) experiments were undertaken to verify that the effects seen
were due to transcriptional induction by vGPCR. Primers for
ampliﬁcation of immunoprecipitated DNA were directed to promoter
and 3′ regions of the CCL2 gene (Fig. 2A). CCL2 promoter-associated
PolII was enhanced by Dox-induced vGPCR expression (Fig. 2B),
thereby conﬁrming transcriptional regulation of CCL2 by the viral
receptor. Around 3-fold induction of CCL2 promoter-associated PolII
in response to vGPCR expression was evident from qPCR analysis of
precipitated DNA (Fig. 2C, left). A similar result was obtained by
analogous comparison of uninfected andHHV-8 de novo infected TIME
cells (Fig. 2C, right), indicating transcriptional induction of CCL2 by
infection also.
CCL2 promoter, enhancer and 3′ regions, containing demonstrated
or predicted transcription factor binding sites (Fig. 2A), had previously
been implicated in transcriptional regulation of CCL2 (Abraham et al.,
2005; Mukerjee et al., 2008; Tanimoto et al., 2008; Ueda et al., 1994;
Wolter et al., 2008). Using appropriate antibodies for ChIP and PCR
primer pairs to these regulatory regions (Fig. 2A), the potential
involvement of NF-κB, Jun, ATF2, Ets-1 and C/EBPβ in regulation of the
chemokine gene by vGPCR was investigated. This series of ChIP assays
identiﬁed vGPCR-induced association of C/EBPβ, speciﬁcally, with
regions of the CCL2 gene corresponding to 5′ promoter and 3′ distal
sequences, ampliﬁed by PCR primer pairs 4 and 6 (Fig. 2D). Putative C/
EBPβ binding sites lie immediately adjacent or close to the PCR-
ampliﬁed products (well within 300 bp, the approximate upper size
limit of sonicated, immunoprecipitatedDNA). These data indicated thee element (TRE)-vGPCR transduced, rtTA transactivator-expressing TIME cells for Dox-
) in indirect immunoﬂuorescence assay (top) and immunoblotting (bottom). EV, empty
lls treated with Dox (vGPCR+) or mock treated (control) for 24 h. Cells were either
um-contained factors) for 24 h prior to addition of Dox. Extracted total RNA from these
rials and methods). Sections of the array corresponding to CCL2 and “housekeeping”
a for CCL2 induction by SYBR green-based qRT-PCR analysis of CCL2 mRNA levels (left)
cultures. qRT-PCR values were normalized to 18S RNA levels determined in parallel real-
r ELISA, duplicate cultures were analyzed and protein concentrations (in culture media)
Fig. 2. Transcriptional analysis of vGPCR-mediated CCL2 induction. (A) Diagrammatic representation of the CCL2 gene, indicating regions and associated putative or demonstrated
transcription factor binding sites implicated by previous studies in transcriptional regulation. Predicted C/EBP binding sites, identiﬁed by application of TFSEARCH (www.cbrc.jp/
research/db/TFSEARCH.html) are shown in grey. The CCL2 mRNA structure is indicated, along with the map positions of the products of PCR primer pairs used for ChIP assays.
(B) Ethidium bromide agarose gel analysis of PCR products derived from chromatin immunoprecipitation (ChIP) assays using antibodies to RNA polymerase II for precipitation of
PolII-bound DNA. Two sets of primer pairs, one directed to proximal promoter sequences and the other to sequences 3′ of the CCL2 gene, were used for PCR-mediated ampliﬁcation of
precipitated DNA. The former, speciﬁcally, was able to give rise to PCR products, which were increased in amplitude as a function of vGPCR expression (+Dox), indicative of receptor-
mediated induction of CCL2 gene transcription. Normal IgG was used as a negative control to ensure speciﬁcity of DNA precipitation by PolII antibody. (C) Quantiﬁed ChIP data using
primer pair 4 for qPCR analysis of PolII-associated and -precipitated DNA derived fromDox-treated ormock-treated TIME-vGPCR cells (left, TRE-vGPCR), conﬁrming the data in panel
B. Equivalent analysis of CCL2 promoter-associated PolII in response to HHV-8 de novo infection of TIME cells provided similar evidence of transcriptional induction of CCL2, 24 h
post-inoculation (right, de novo infn). Error bars indicate deviation from mean values obtained from duplicate PCR reactions. (D) Analogous ChIP assays to investigate the potential
relevance of a panel of transcription factors to vGPCR-mediated regulation of CCL2. Several PCR primer pairs (1–6) directed to different regions of the CCL2 locus were used for PCR
ampliﬁcation of precipitated DNA. Each was pre-validated to ensure ability to amplify “input” cellular DNA (data not shown). vGPCR-induced promoter-association of C/EBPβ,
exclusively, was detected, speciﬁcally with regions ampliﬁed by PCR primer pairs 4 and 6 (right chart). Error bars indicate deviation from mean values obtained from duplicate PCR
reactions.
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potential relevance of promoter-proximal and 3′ cis-elements in this
activity. To test the latter, these sequences were cloned into a
luciferase reporter plasmid, in their appropriate 5′ and 3′ positions,
and transfected into HEK293 T cells. The 5′ region (−560/+1), alone,
was responsive to vGPCR expression (Fig. 3A). To better deﬁne
responsive sequences within the 5′ region, deletion mutagenesis was
undertaken, and single or combined mutagenesis of the putative C/
EBPβ binding sites was carried out to test directly the relevance of
these elements. The respective reporter constructions were used in
transfection experiments, as before. The results revealed that deletion
of sequences between −320 and −240, containing the proximal C/
EBP consensus site, led to loss of vGPCR responsiveness and that
speciﬁc mutation of the proximal C/EBP cis-element, but not the more
distal site, was alone sufﬁcient to abrogate vGPCR-mediated induction
(Fig. 3B). These data, taken together with the ChIP analysis, indicated
the signiﬁcance of C/EBPβ and the proximal C/EBP site at −256 to
−263 for transcriptional induction of CCL2 by vGPCR.To verify the targeting and activation of C/EBPβ by vGPCR, EMSA
and immunoblotting approaches were employed. For EMSA, a wild-
type C/EBP probe or a C/EBP site-mutated version (see Materials
and methods) were mixed with nuclear extracts derived from
parallel cultures of TIME-vGPCR cells either treated with Dox
(vGPCR+) or left untreated, prior to PAGE analysis. Formation of
C/EBP binding site dependent DNA–protein complexes was in-
creased as a function of vGPCR expression (Fig. 4A). These
complexes could be competed with an excess of unlabeled wild-
type but not C/EBP core sequence-mutated probe (lanes 4-7),
conﬁrming interaction speciﬁcity. That C/EBPβ comprised a major
component of the detected complexes was evidenced by their
supershifting with addition of C/EBPβ antibody (Fig. 4A, lanes 8 and
9). Antibody to NF-κB component p65, used as a negative control,
did not affect migration of the complexes (Fig. 4A, lanes 10 and 11).
Together, the EMSA data indicated that C/EBPβ was a target of
activation by vGPCR signaling. This was veriﬁed by immunoblotting
for phosphorylated (activated) C/EBPβ at various times after Dox
Fig. 3. Luciferase-based reporter assays to investigate possible contributions of 5′ promoter and 3′ regions to CCL2 induction by vGPCR. (A) Reporter constructions containing either
or both of these regions were generated in pGL3basic (GL3b) transfected into HEK293 T cells together with either vGPCR expression vector or empty vector control. The 5′ region,
corresponding to−560/+1, was activated by vGPCR, but the 3′ sequences alone were unresponsive and did not contribute to vGPCR-induced luciferase expression when present
with the 5′ region. Error bars indicate standard deviations from mean values obtained from triplicate transfections. Arrowheads indicate putative C/EBPβ binding sites. (B)
Analogous assays were undertaken using the −560/+1 reporter or deleted or C/EBP site-mutated versions thereof. The results obtained demonstrated the involvement of
promoter–proximal sequences and speciﬁcally the−256/−263 C/EBP consensus site in vGPCR-mediated CCL2 induction. Mutation of the distal putative C/EBP-binding site did not
affect CCL2 induction by vGPCR.
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used for Western blotting was directed to threonine-235, a known
target of the mitogen activated protein kinase (MAPK) ERK and
phosphorylation of which leads to activation of C/EBPβ DNA
binding and transcriptional activity (Hu et al., 2001; Hungness et
al., 2002). Phosphorylation of C/EBPβ was induced rapidly (within
3 h) by Dox treatment, with levels of total C/EBPβ unchanged
(Fig. 4B, top two panels). Consistent with these ﬁndings, concom-
itant phosphorylation (activation) of C/EBPβ-activating ERK was
detected in response to Dox-induced vGPCR expression (Fig. 4B,
middle two panels). Kinetics of Dox-induced vGPCR expression, as
determined by Western blotting (Fig. 4B, bottom two panels),
matched the activation proﬁles of C/EBPβ and ERK. Thus, our EMSA
and immunoblotting data demonstrate that vGPCR can induce
activation of C/EBPβ in endothelial cells, consistent with the ChIP
data implicating C/EBPβ as a potential effector of CCL2 induction by
vGPCR (Fig. 2).
To address directly the relevance of C/EBPβ for vGPCR-mediated
CCL2 induction, TIME cells expressing either of two active C/EBPβ-directed shRNAs (Fig. 5A) or non-silencing (NS) shRNA control were
transduced with vGPCR-expressing or empty lentiviral vectors.
Following incubation for 24 h, mRNA was extracted for qRT-PCR
analysis of CCL2 transcript levels. vGPCR-induced CCL2 mRNA
expression was diminished strongly by C/EBPβ depletion by each of
the C/EBPβ shRNAs, but not by the NS control shRNA, conﬁrming the
importance of C/EBPβ for vGPCR-induced CCL2 expression (Fig. 5B). A
similar experiment was undertaken in the absence and presence of
MEK (ERK kinase) inhibitor PD98059, demonstrating the importance
for vGPCR-mediated CCL2 induction of MAPK pathway activation,
consistent with C/EBPβ activation being mediated via this route
(Fig. 5C). In contrast, PD98059 had no effect on TNFα-mediated CCL2
activation, demonstrating the speciﬁcity of action of theMEK inhibitor.
Finally, experiments were undertaken to assess the relevance of
vGPCR and C/EBPβ to CCL2 induction in the context of HHV-
8 infection. De novo infection of TIME cells with BCBL-1 derived
HHV-8 (as described previously; Choi and Nicholas, 2008) and qRT-
PCR analysis of CCL2 mRNA expression at different times (0–3 days)
post-infection veriﬁed the induction of CCL2 by HHV-8 (Fig. 6A),
Fig. 4. C/EBPβ as a target of vGPCR activation. (A) EMSA for veriﬁcation of C/EBPβ activation by vGPCR. A double-stranded, [32P]-labeled probe containing a C/EBPβ binding core
sequence was used to identify C/EBPβ activity in nuclear extracts of TIME-vGPCR cells, untreated or treated with Dox for 24 h. A probe mutated in the C/EBPβ binding sequence (mt
C/EBP) was used as a control (lanes 12–14). Protein–DNA complexes were evident speciﬁcally on the wild-type probe, and these were induced by Dox treatment. The complexes
could be supershifted with antibody speciﬁc for C/EBPβ, but not by antibody to NF-κB p65 (negative control), demonstrating the presence of C/EBPβ in the complexes. The
complexes were also competed with excess unlabeled wild-type (wt) ds-oligonucleotide, but not by its mutated counterpart (mt). Input, probe loaded directly onto the gel without
prior incubation with nuclear extract. (B) Immunobotting for detection of vGPCR-activated C/EBPβ. Antibody speciﬁc for Thr235-phosphorylated C/EBPβ was used to detect and
determine relative levels of activated C/EBPβ in untreated TIME-vGPCR cells (time 0) and at various times (3–9 h) post-Dox induction of vGPCR expression. An appropriate antibody
subsequently was applied to the stripped blot to detect total C/EBPβ, thereby providing a control for equal protein loading. Analogous analysis of induced phosphorylation
(activation) of ERK (C/EBPβ kinase, targeting Thr235) also was undertaken (middle panels). Expression of vGPCR in response to Dox treatment of TIME-vGPCR cells was conﬁrmed
by Western blotting; probing for chemokine receptor CCR8 provided a protein-load control (bottom two panels).
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et al., 2007). The involvement of vGPCR in this process was addressed
by its depletion, using two pre-validated shRNAs (Fig. 6B). These were
transduced into TIME cells using lentiviral vectors [to achieve an
infection rate (GFP+) of N90%], and cultures subsequently infected
with HHV-8. Each of the vGPCR-directed shRNAs led to dramatic
reductions, relative to control NS shRNA, of qRT-PCR-detected CCL2
induction by HHV-8 infection (Fig. 6C, top). Measurements of secreted
CCL2 protein levels in NS and vGPCR-sh2 shRNA-transduced cultures
after 2 and 3 days of Dox treatment (Fig. 6C, bottom) reﬂected the
qRT-PCR results. These data provide strong evidence of the involve-
ment of and requirement for vGPCR in HHV-8-induced CCL2
expression. The depletion approach was also used to address the
relevance of C/EBPβ for CCL2 induction by HHV-8 infection. Cells
expressing either of our two C/EBPβ shRNAs (Fig. 5A) showed
diminished CCL2 induction in response to HHV-8 de novo infection,
thereby conﬁrming the involvement of C/EBPβ in this process (Fig.
6D). The relevance of vGPCR in activation of C/EBPβ in the context of
HHV-8 infection was veriﬁed by immunoblotting for phosphorylated
(activated) C/EBPβ in the absence and presence of vGPCR depletion in
cells infected de novo with HHV-8; C/EBPβ activation was reduced
signiﬁcantly in vGPCR shRNA-transduced cells (Fig. 6E). Appropriate
infection of TIME cells and expression of vGPCR was checked by
infection of cultures under identical conditions and detection by
immunoﬂuorescence staining of vGPCR. Co-staining for latency-
associated nuclear antigen (LANA), expression of which occurs within
hours after de novo infection and persists during subsequent latent
infection of inoculated cells (Sadagopan et al., 2007; Sharma-Walia et
al., 2005), was undertaken to identify infected cells. High infection
rates (LANA+ cells) were detected, and most of these cells also
expressed detectable levels of vGPCR at 24 h post-infection (Fig. 6F).
These data demonstrate the rapid and widespread expression of
vGPCR in endothelial cells following de novo infection.
The mechanism by which vGPCR might contribute to KS
pathogenesis is unclear, but present evidence favors a paracrinefunction of vGPCR in viral pathogenesis, because vGPCR expression
has been detected only during lytic replication. Data presented here as
well as previously (Caselli et al., 2007) indicate that CCL2 is a host
cytokine that can escape virus-induced host shutoff (Glaunsinger and
Ganem, 2004a, 2004b) and potentially contribute to KS via its
angiogenic activity. While it has been reported that HHV-8 infection
of endothelial cells activates NF-κB and that this is important for
virus-mediated CCL2 induction, the reporter-luciferase experiments
presented in this previous study in fact showed that mutation of NF-
κB cis-elements affected overall CCL2 promoter activity rather than
fold-induction by HHV-8 infection (Caselli et al., 2007). Indeed, this
study reported that other NF-κB-inducible cytokines, such as CXCL8/
IL-8 and CCL5/RANTES, were not induced by HHV-8 infection. In
agreement with this previous study, we found that CCL2 was the
major angiogenic/pro-inﬂammatory cytokine induced by HHV-
8 infection. However, our analysis of endogenous CCL2 promoter-
associated transcription factor activation by ChIP assays identiﬁed C/
EBPβ activation as of likely primary relevance rather than NF-κB
activation. This was veriﬁed by C/EBPβ depletion experiments
showing marked diminution of HHV-8 mediated CCL2 induction in
the presence of C/EBPβ-directed shRNAs. Furthermore, vGPCR
depletion led to almost complete loss of CCL2 induction in response
to HHV-8 infection. Thus, while other viral signaling proteins, such as
vIL-6 and K15 encoded membrane protein, shown to induce CCL2 in
experimental systems (Brinkmann et al., 2007; Fielding et al., 2005),
can potentially contribute to this process, our data implicate vGPCR as
critically important. Data from our ChIP and reporter assays indicate
that C/EBPβ binding to the CCL2 promoter is induced by vGPCR, that
at least one vGPCR-responsive element of the CCL2 promoter lies
within the−560/+1 region and that the putative C/EBP binding site
at−256 to−263 is functionally signiﬁcant. We have not ruled out the
possibility that other functionally relevant C/EBPβ-binding cis-
elements may lie outside this region, however. Further studies will
be required to determine whether other promoter and/or enhancer
elements are involved in responsiveness of the CCL2 promoter to
Fig. 5. C/EBPβ as a mediator of CCL2 induction by vGPCR. (A) Immunoblot-based
analysis of C/EBPβ depletion in TIME-vGPCR cells transduced with either of two
lentiviral vector-delivered shRNAs speciﬁc for C/EBPβ mRNA (sh1, sh2) as compared
with control cells transduced with non-silencing (NS) shRNA. Actin antibody was used
as a protein load control. (B) Dependency of vGPCR-induced CCL2 expression on C/
EBPβ. NS or C/EBPβ shRNA-transduced TIME cells infected subsequently with vGPCR-
encoding or empty lentivirus vectors were assessed by qRT-PCR analysis of extracted
RNA for CCL2 mRNA expression. The data (top panel) revealed dependence of vGPCR-
mediated induction of CCL2 on C/EBPβ expression, providing evidence of direct
involvement of the transcription factor in this response. Expression of vGPCR in
receptor expression vector-transduced cells was veriﬁed by qRT-PCR (bottom panel).
Error bars indicate deviation from mean values obtained from duplicate PCR reactions.
(C) Involvement of MAPK signaling in vGPCR-mediated CCL2 induction. CCL2 mRNA
expression was quantiﬁed by qRT-PCR, as before, in TIME-vGPCR cells mock treated or
treated with Dox in the absence (DMSO) or presence of MEK (ERK kinase) inhibitor
PD98059 (50 μM). The results (left) demonstrated substantial inhibition of CCL2
induction in the presence of PD98059. A parallel analysis of CCL2 induction by TNFα
(10 ng/ml), which activates CCL2 via NF-κB signaling, showed no inhibition by the MEK
inhibitor, thereby indicating the absence of non-speciﬁc effects mediated by drug
treatment.
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contributions of other HHV-8 signaling proteins. Notwithstanding, the
data presented here identify vGPCR as essential for activation of CCL2
expression by HHV-8 de novo infection of endothelial cells and
establish that this activity is mediated primarily by C/EBPβ activation
via MAPK pathway signaling.
Materials and methods
Plasmids and oligonucleotides
HHV-8 open reading frame 74 (ORF74, encoding vGPCR) was
cloned between the BamHI and MluI sites of pRetroX-Tight-Pur
(Clontech Laboratories Inc., Mountain View, CA). Human genomic
DNA fragments encompassing CCL2 promoter (−560 to +60),
truncated versions thereof, or 3′ region of the CCL2 gene (UTR + 3′
region, +1539 to +2558) were ampliﬁed and cloned between the
MluI and XhoI sites or into the XbaI site, respectively, of pGL3 basic
(Promega, Madison, WI). Complementary pairs of 59-nucleotide
oligonucleotides encoding a 21-nucleotide short hairpin RNA
(shRNA) to C/EBPβ (sh1: 5′-cccgtggtgttatttaaagaa-3′ and sh2: 5′-
tgtgtacagatgaatgataaa-3′) and vGPCR (sh1: 5′-agcggatatgactactctgga-3′
and sh2: 5′-aacgttggaatactctctctg-3′) mRNA sequences, or non-silenc-
ing (NS) control (Choi and Nicholas, 2008), were annealed and cloned
between the BamHI and MluI sites of lentiviral vector pYNC352
(Choi and Nicholas, 2008). Primer sequences used for quantitative PCR
were the following: CCL2 forward primer (5′-aagatctcagtgcagaggctcg-
3′); CCL2 reverse primer (5′-ttgcttgtccaggtggtccat-3′); vGPCR forward
primer (5′-gtggtgccttacacgtggaa-‘3); vGPCR reverseprimer (5′-gcgagtt-
taggcagatacccag-3′); 18S forward primer (5′-cgcggttctattttgttggt-3′);
18S reverse primer (5′-ccctcttaatcatggcctca-3′). Primer sequences used
for ChIP were the following: forward primer-1 (5′-ctggaatgcaggctc-
cagcca-3′); reverse primer-1 (5′-cctttgcatatatcagacagt-3′); forward
primer-2 (5′-ccttgagcaggctatttaacc-3′); reverse primer-2 (5′-cttgga-
caaaggcatagacag-3′); forward primer-3 (5′-ttaatgcattgtcagggagcc-3′);
reverse primer-3 (5′-ggaagcgaggaaactagatga-3′); forwardprimer-4 (5′-
tggcaccccatcctccccatt-3′); reverse primer-4 (5′-ctctcggttcctctggctgct-
3′); forward primer-5 (5′-gtaaggccccctcttcttctc-3′); reverse primer-5
(5′-ccagagctggaatcctggaag-3′); forward primer-6 (5′-ccagatgc-
gaattcgggccca-3′); reverse primer-6 (5′-tggaccatggcaatagcttct-3′). PCR
products using primer pairs 1–5 correspond to CCL2 promoter/
enhancer sequences −2459 to −2639, −766 to −560, −454
to −327, −240 to −1, and +33 to +369, respectively, and
primer pair 6 ampliﬁes the +2550 to +2807 region 3′ of the
mRNA coding sequences. Progressively 5′-deleted segments of the
CCL2 promoter region were obtained by PCR using the following
primers in concert with +60-reverse primer (5′-ggctggaggcga-
gagtgcgagc-3′): −560-forward (5′-gtctgaaaccctagaactctt-3′); −480-
forward (5′-ttctgcatttgaatgagcaaa-3′); −400-forward (5′-
ggccccttggaatgtggcctg-3′); −320-forward (5′-tctgcagttttcgcttcagag-
3′); −240-forward (5′-tggcaccccatcctccccatt-3′); −160-forward
(5′-tttcctacttcctggaaatcc-3′); −80-forward (5′-ctcctcctgcttgactccgcc-
3′). Mutagenesis of putative C/EBP sites within the promoter
region was carried out using Pfx DNA polymerase in PCR-based
procedures to replace C/EBP sites (positions −516 to −523 and
−256 to −263) with an SpeI site-containing sequence (cAC-
TAGTc), used for subsequent identiﬁcation of luciferase reporter-
cloned mutated promoter sequences. Primers used for mutagenic
PCR were −520F-C/EBP-mut (5′-cttagaattcagttcaatgtCACTaGTCtcc-
tacagttctgctaggct-3′; upper case, mutated nucleotides); −520R-C/
EBP-mut (reverse complement of −520F-C/EBP-mut); −260F-C/
EBP-mut (5′-aataaccctcttagttcacaCACTAgTCcagtctgggcttaatggcac-3′);
−260R-C/EBP-mut (reverse complement of −260F-C/EBP-mut).
Primer sequences used for EMSA were the following: C/EBPβ
(5′-tgcagattgcgcaatctgca-3′) and mutated C/EBPβ (5′-tgcagagac-
tagtctctgca-3′), together with the respective complements.
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RNA polymerase II (N-20), NF-κB p65 (A), C/EBPβ (C-19), Ets-1
(C-20), c-Jun (D), and ATF-2 (N-96) antibodies were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); phospho-C/EBPβ
(Thr235), phospho-Erk1/2 (Thr202/Tyr204), and Erk1/2 antibodies
were purchased from Cell Signaling Technology, Inc. (Beverly, MA); β-
actin antibody was purchased from Sigma (St. Louis, MO); CCR8 and
GFP antibodies were from Epitomics, Inc. (Burlingame, CA). ELISA for
CCL2/MCP-1 was undertaken using reagents and procedures from
Peprotech (Rocky Hill, NJ) to determine CCL2 protein concentrations
in culture media. Previously described rabbit antiserum directed to
the N-terminal region of vGPCR (Chiou et al., 2002) was kindly
provided by Dr. Gary Hayward.
Cell culture, transfection, transduction, and infection
Telomerase immortalized microvascular endothelial (TIME) cells
(Venetsanakos et al., 2002) were maintained in EGM-2 MV medium
(Lonza, Walkersville, MD) containing 5% fetal bovine serum (FBS) and
cytokine supplements. HEK293 T cells were grown in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% FBS and gentami-
cin. BCBL-1 cells were cultured in RPMI 1640 supplemented with 20%
heat-inactivated FBS and gentamicin. For virus vector production or
reporter assays, HEK293 T cells were transiently transfected with
plasmid DNA using standard calcium phosphate co-precipitation.
Stable transduction of TIME cells with retrovirus (for shRNA
expression) or lentivirus (for protein expression) was performed
under puromycin selection. Infectious HHV-8 virus was obtained by
inducing BCBL-1 cells with phorbol 12-myristate 13-acetate (PMA;
20 ng/ml) and calcium ionophore (A23187; 500 ng/ml). After 20 h,
cells were pelleted and resuspended in fresh medium without PMA
and A23187. After 4 days, virions were pelleted from culture media by
centrifugation at 15,000 rpm for 2 h in an SW41 rotor. For HHV-
8 infection of TIME cells, the viral pellet was resuspended in basal
EGM-2 MV medium supplemented with Polybrene (5 μg/ml) and
added to cell cultures for 2 h, prior to replacement of inoculum with
fresh medium. In experiments to determine the inﬂuence of virus-
produced vGPCR on C/EBPβ phosphorylation, culture medium
containing 1% serum and no cytokine supplements was employed to
minimize background (non-virus-induced) C/EBPβ activation.
Membrane array expression analysis
Total RNA from TIME-vGPCR cells treated with 1 μg/ml doxycy-
cline ormock treated (carrier, DMSO, only) for 24 hwere isolatedwith
the RNeasy RNA puriﬁcation kit (Qiagen, Valencia, CA). RNA was
reverse transcribed using the TrueLabeling-AMP™ 2.0 kit (Superarray,
Frederick, MD), to obtain cDNA and converted into biotin-labeled
cRNA using biotin-16-UTP (Roche Applied Science, Indianapolis, IN)
by in vitro transcription. cRNA probes were puriﬁed with the
ArrayGrade cRNA cleanup kit (Superarray) and then hybridized to
the pretreated Oligo GEArray® Human Angiogenesis Microarray OHS-
024 (Superarray). Following several washing steps, array spots
binding cRNA were detected using alkaline phosphatase-conjugated
streptavidin and CDP-Star as chemiluminescent substrate and
visualized on X-ray ﬁlm.
Quantitative RT-PCR
First-strand cDNA was synthesized from 1 μg of total RNA using
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) with
random hexamers. SYBR green-based quantitative PCR was per-
formed using the 7500 real-time PCR system (Applied Biosystems,
Carlsbad, CA). PCR conditions included an initial incubation step of
2 min at 50 °C and an enzyme heat activation step of 10 min at 95°C,followed by 50 cycles of 15 s at 95 °C for denaturing and 1min at 60 °C
for annealing and extension.
Immunoblotting and Immunoﬂuorescence assay
For general immunoblotting, cellswere lysed in lysis buffer (50mM
Tris–HCl [pH 8.0], 150mMNaCl, 1mMEDTA, 1% IGEPAL CA-630, 0.25%
sodium deoxycholate, and protease and protein phosphatase inhibitor
cocktails). For extraction of integral membrane proteins vGPCR and
CCR8, cell pellets were suspended in 0.25 M sucrose supplemented
with protease inhibitors and cells disrupted by sonication; nuclei were
removed by centrifugation at 1000 g for 10 min and membranes
pelleted by centrifugation at 200,000 g for 1 h, prior to protein
solubilization in CHAPS buffer (100 mM Tris–HCl, [pH 7.4], 50 mM
NaCl, 5 mM EDTA, and 1% CHAPS) overnight at 4 °C. Cell extract- or
membrane-derived proteinswere size fractionated by sodiumdodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to a nitrocellulose membrane. Immunoreactive bands were
detected with enhanced chemiluminescence solution (GE Healthcare,
Piscataway, NJ) and visualized on X-ray ﬁlm. For immunoﬂuorescence
assay (IFA), cells on a 0.1% gelatin-coated coverglass were ﬁxed and
permeabilized in chilled methanol. Following incubation with block-
ing buffer (3% bovine serum albumin in PBS), coverslips were
incubated with primary antibody, washed with phosphate-buffered
saline (PBS), and then incubated with appropriate ﬂuorescent dye-
conjugated secondary antibody. Coverslips were mounted in 90%
glycerol in PBS containing 10 mg/ml p-phenylenediamine. Nuclei
were visualized by staining with Hoechst 33342.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed according to the protocol of Nelson et al.
(2006). Brieﬂy, cells were ﬁxed with formaldehyde in a ﬁnal
concentration of 1.42% for 10 min at room temperature and then
incubated with 125 mM glycine for 5 min at room temperature to
quench the formaldehyde. The cells were washed with ice-cold PBS
twiceand lysed in1ml of immunoprecipitatin (IP) buffer (150mMNaCl,
50mMTris–HCl [pH 7.5], 5mMEDTA, 0.5% IGEPAL CA-630, 1% Triton X-
100, and protease inhibitor cocktail). The lysates were centrifuged at
12,000 g for 1min at 4 °C. The nuclear pellet waswashedwith IP buffer,
resuspended in 400 μl of IP buffer, and then sonicated 10 times by 20-s
pulses on ice under the 30% amplitude setting of Branson sonicator 185
(Danbury, CT). The lysate was cleared by centrifugation at 12,000 g for
10 min at 4 °C and incubated with the antibody for 12 h. The immune
complex was precipitated with protein A-agarose and then washed six
times with 1 ml cold IP buffer. DNA fragments in the complex were
released by boiling for 5 min with 10% Chelex 100 slurry. The
supernatant was treated with proteinase K (200 ng/ml) at 55 °C for
30 min and then boiled for 10 min. DNA fragments were puriﬁed with
phenol/chloroform, concentrated by ethanol precipitationwith 20 μg of
glycogen, and subjected to quantitative PCR. DNA copy number was
determined from a standard curve generated by each primer set with
known amounts of genomic DNA.
Reporter assay
HEK293 T cells were transiently transfected with pSG5 or pSG5-
vGPCR plasmids along with reporter plasmids for 24 h and then lysed
with passive lysis buffer (Promega, Madison, WI). Luciferase activity
was measured by standard protocol using D-luciferin.
Electrophoretic mobility shift assay
Nuclear extracts fromdoxycycline-treatedoruntreatedTIME-vGPCR
cells were prepared by homogenization using buffer A (10 mM HEPES
[pH8.0], 1.5mMMgCl2, 10mMKCl, 0.5mMDTT, andprotease inhibitor)
376 Y.B. Choi, J. Nicholas / Virology 397 (2010) 369–378and after centrifugation resuspending pellet in buffer B (20 mMHEPES
[pH 8.0], 1.5 mMMgCl2, 420 mMNaCl, and 0.2 mM EDTA). The nuclear
extracts (10 μg protein) were incubated in the presence of 2 ng of
radiolabeled oligonucleotides in binding buffer (10 mM Tris–HCl, pH
8.0, 150mMKCl, 0.2 mMDTT, 0.5 mMEDTA, 12.5% glycerol, and 1 μg of
poly(dI-dC)). For supershift assay, the nuclear extracts were incubated
with 200 ng of appropriate antibodies for 30 min at room temperature
and then for 15 min with the oligonucleotide. For competition assay,20 ng of unlabeled oligonucleotide was added to the reaction mixture.
Complexes were electrophoresed on 4% acrylamide gel and visualized
by autoradiography.
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